Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
June 16, 2024 06:10 ET
|
Regeneron Pharmaceuticals, Inc.
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% overall response rate, as presented in an EHA oral presentation and simultaneously...
Sprout Social Recognized by Fortune Media as a Best Workplace in Chicago for the Third Consecutive Year
June 14, 2024 09:00 ET
|
Sprout Social, Inc
CHICAGO, June 14, 2024 (GLOBE NEWSWIRE) -- Sprout Social, an industry-leading provider of cloud-based social media management software, has been named to the 2024 Fortune Best Workplaces in Chicago™...
ORYZON Presents Preliminary Data From Ongoing Phase Ib FRIDA Trial with Iadademstat Plus Gilteritinib in Relapsed/Refractory FLT3-mut AML Patients at EHA-2024
June 14, 2024 08:00 ET
|
Oryzon Genomics, S.A.
Data from the first two cohorts demonstrated that combination of iadademstat plus gilteritinib was safe and showed strong antileukemic activityA third cohort is ongoing following FDA’s OPTIMUS...
La SOGC demande un cadre national pour la collecte de données sur la mortalité maternelle
June 14, 2024 05:59 ET
|
La Société des obstétriciens et gynécologues du Canada
EDMONTON, Alberta, 14 juin 2024 (GLOBE NEWSWIRE) -- La mort de toute femme suite à une grossesse ou à un accouchement est une tragédie, et pourtant, le Canada ne fait pas assez pour prendre les...
SOGC Calls for National Framework for Maternal Mortality Data Collection
June 14, 2024 05:59 ET
|
The Society of Obstetricians and Gynaecologists of Canada
EDMONTON, Alberta, June 14, 2024 (GLOBE NEWSWIRE) -- The death of any one woman as a result of pregnancy or childbirth is too many, yet Canada is not doing enough to take steps that could prevent...
Updated Phase 2 CAPTIVATE study results demonstrate sustained clinical benefit of fixed-duration IMBRUVICA® (ibrutinib) plus venetoclax as first-line treatment for patients with chronic lymphocytic leukaemia, including those with high-risk disease
June 14, 2024 03:13 ET
|
Janssen Cilag International NV
At 5 years, 67 percent of patients were progression-free, with overall survival at 96 percent for all treated patients 1 BEERSE, BELGIUM, June 14, 2024 (GLOBE NEWSWIRE) --...
Findings from landmark RESONATE-2 study confirm sustained survival benefit of IMBRUVICA® (ibrutinib) for first-line chronic lymphocytic leukaemia treatment with up to 10 years follow-up
June 14, 2024 03:00 ET
|
Janssen Cilag International NV
RESONATE-2 data presented at the 2024 European Hematology Association (EHA) Congress provide longest-term outcomes and safety data ever reported for a monotherapy BTK inhibitor, with a median PFS of...
Telenor etablerer nytt cybersikkerhetsselskap med nordiske ambisjoner
June 14, 2024 00:30 ET
|
Telenor
(Fornebu, 14. juni 2024) Norsk næringsliv og offentlige virksomheter blir stadig utsatt for flere og mer alvorlige cyberangrep. 1 av 5 bedriftsledere sier at de har erfart cyberangrep det siste året,...
Telenor Establishes New Cyber Security Company with Nordic Ambitions
June 14, 2024 00:30 ET
|
Telenor
Fornebu, Norway – June 14, 2024 – Norwegian businesses and public sector organisations are facing more frequent and severe cyberattacks. According to a survey conducted by Norstat, 1 in 5 business...
Updated: Breast Surgery Collaborative Community issues consensus statement on breast implant capsulectomy definitions and management
June 13, 2024 16:11 ET
|
American Society of Plastic Surgeons
Arlington Heights, Ill, June 13, 2024 (GLOBE NEWSWIRE) -- A consensus statement on the terminology and management of breast implant capsules issued by the Breast Surgery Collaborative Community...